David Riggins was charged in Nevada state court with murder and robbery. While detained pretrial, he complained of hearing voices and was prescribed the antipsychotic drug Mellaril (thioridazine). As the case progressed, Riggins notified the court he would assert insanity/diminished capacity defenses and moved to suspend the drug's administration during trial so the jury could evaluate his true mental condition and so he could meaningfully participate in his defense. After a brief hearing, the trial court denied the motion and ordered that Riggins continue to receive antipsychotic medication throughout trial without making specific findings that medication was medically appropriate and essential or that no less intrusive alternative would suffice. Riggins proceeded to trial while medicated, was convicted of murder and robbery, and was sentenced to death. The Nevada Supreme Court affirmed. The U.S. Supreme Court granted certiorari to decide whether the State's involuntary administration of antipsychotic drugs during trial violated Riggins's constitutional rights.
Does the State violate a defendant's due process and fair trial rights by administering antipsychotic medication during trial over the defendant's objection without first making findings that the treatment is medically appropriate and necessary, considering less intrusive alternatives?
The Due Process Clause protects a significant liberty interest in freedom from the unwanted administration of antipsychotic drugs. The State may not administer such medication to a defendant during trial over his objection unless it demonstrates, and the court finds on the record, that (1) the treatment is medically appropriate; (2) it is necessary to further essential state interests (such as the safety of the defendant or others or the integrity of the trial process), and (3) less intrusive alternatives have been considered and found inadequate. Any order permitting involuntary medication must rest on case-specific findings sufficient to allow meaningful appellate review.
Yes. The State violated due process by medicating Riggins during trial without on-the-record findings of medical appropriateness and necessity and without considering less intrusive alternatives. The conviction and sentence were reversed and remanded.
The Court began by reaffirming that individuals possess a constitutionally protected liberty interest in avoiding forced administration of antipsychotic drugs, citing Washington v. Harper. Antipsychotics can have profound effects on a person's mind and body, including sedation and changes in affect, which may alter a defendant's demeanor, ability to communicate, and the jury's assessment of his mental state—especially where sanity or intent is disputed. These concerns implicate both due process and core Sixth Amendment trial rights, such as the right to consult with counsel, to be present in a meaningful way, and to present a defense. In the trial context, the State's interests—such as ensuring safety in the courtroom and maintaining an orderly, fair proceeding—can be important. But those interests do not automatically override a defendant's liberty interest. At a minimum, trial courts must make findings that the proposed treatment is medically appropriate and necessary to further those essential interests and that less intrusive alternatives would be ineffective. The Court analogized to Harper's standard for prison settings and concluded that equal or greater procedural rigor is required when medication would be administered at a criminal trial. Here, the trial court permitted medication throughout Riggins's trial without articulating why it was necessary, whether it was in his best medical interest, or why less restrictive options would not suffice. This absence of findings prevented meaningful appellate review and failed to ensure that the defendant's trial rights were protected. Given the plausible ways the medication could have influenced the jury's perception of Riggins's mental condition and his ability to assist counsel, the State could not show the error was harmless beyond a reasonable doubt. The Court therefore reversed and remanded. The Court expressly declined to adopt a categorical rule forbidding involuntary medication at trial; instead, it required rigorous, case-specific justification. It also left for another day the question of when, if ever, medication may be compelled solely to restore trial competence (later addressed in Sell v. United States).
Riggins sets the baseline constitutional framework for involuntary medication in the trial setting. It requires trial judges to make explicit, reviewable findings of medical appropriateness, necessity, and the inadequacy of less intrusive alternatives before allowing antipsychotic medication over a defendant's objection. For law students, Riggins is a pivotal due process and fair trial case that: (1) operationalizes bodily integrity principles from Harper in the courtroom, (2) highlights how medication can distort a jury's assessment of sanity and mens rea, and (3) anticipates the more detailed competency-restoration standard later announced in Sell. Practically, it instructs defense counsel to build a robust record and instructs courts that silent or perfunctory orders will not withstand constitutional scrutiny.
Riggins v. Nevada underscores that courtroom fairness includes protecting a defendant's bodily integrity and the conditions under which he appears before the jury. When the State seeks to medicate a defendant over objection during trial, it must meet a demanding constitutional threshold: show medical appropriateness, prove necessity to advance essential state interests, and demonstrate that less intrusive measures will not work—all on the record.